Pregled bibliografske jedinice broj: 1225228
Development and validation of a novel CE method for simultaneous analysis of ribociclib, letrozole and ibuprofen
Development and validation of a novel CE method for simultaneous analysis of ribociclib, letrozole and ibuprofen // International conference 19. Ružička days book of abstracts / Babić, Jurislav ; Lauš, Ivana (ur.).
Osijek : Zagreb: Prehrambeno tehnološki fakultet Sveučilišta Josipa Jurja Strossmayera u Osijeku ; Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI), 2022. str. 112-112 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1225228 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Development and validation of a novel CE method
for simultaneous analysis of ribociclib, letrozole
and ibuprofen
Autori
Božić, Josipa ; Mlinarić, Zvonimir ; Turković, Lu ; Nigović, Biljana ; Sertić, Miranda
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
International conference 19. Ružička days book of abstracts
/ Babić, Jurislav ; Lauš, Ivana - Osijek : Zagreb : Prehrambeno tehnološki fakultet Sveučilišta Josipa Jurja Strossmayera u Osijeku ; Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI), 2022, 112-112
Skup
19. Ružičkini dani "Danas znanost - sutra industrija"
Mjesto i datum
Vukovar, Hrvatska, 21.09.2022. - 23.09.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
breast cancer, capillary electrophoresis, ribociclib, letrozole, ibuprofen
Sažetak
Breast cancer is the most common cancer worldwide while the HR+/HER2- subtype is the most prevalent [1]. Locally advanced or metastatic HR+/HER2- breast cancers are treated with the combination of CDK4/6 inhibitors and drugs with anti-estrogen effects. One of the common combinations used in clinical practice is ribociclib with letrozole [2]. Many breast cancer patients suffer from various comorbidities and side effects. Thus, different drug classes are regularly used in clinical practice, painkiller ibuprofen being one of the most common. Because of that, we developed a capillary electrophoresis (CE) method for the simultaneous determination of ribociclib, letrozole, and ibuprofen since drugs metabolized by the same enzymes can have interactions. During method development, different buffer types (borate and phosphate with and without SDS) and additives and surfactants (SBE-β-CD and i-PrOH) were tested. Separation was achieved with 75 mM phosphate, 8.5 mM sulfobutylether-β-cyclodextrin, and 5% i-PrOH. The optimal conditions were 15 kV, 25 °C and 5 s hydrodynamic injection under 50 mbar. The developed method was validated according to the ICH guidelines and was shown to be linear in the range of 1 to 75 µg mL-1 (r>0.9957). Intra-day and inter-day repeatabilities were evaluated for method precision with acceptable RSD values. The robustness of the method was tested by changing applied voltage (± 0.5 kV), cyclodextrin concentration (± 0.5 mM), and temperature (± 2 ºC) one variable at a time, and the changes in peak areas and migration times were shown to be in the range of 0.34 to 7.27 %. The validated method is the basis for the further development of an even more sensitive method capable of detecting low plasma concentrations of these drugs using innovative sample preparation techniques and coupling to the mass detector which could then be applied to standard clinical practice.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Farmacija
POVEZANOST RADA
Projekti:
UIP-2019-04-8461 - Nova bioanalitička rješenja za personalizaciju terapije raka dojke (OncoBioAnalytics) (Sertić, Miranda, HRZZ - 2019-04) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Prirodoslovno-matematički fakultet, Zagreb
Profili:
Lu Turković
(autor)
Biljana Nigović
(autor)
Miranda Sertić
(autor)
Zvonimir Mlinarić
(autor)